Pliant Therapeutics (PLRX) Accounts Payables (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Accounts Payables of $362000.0 for Q1 2026, down 93.56% year-over-year from $5.6 million in Q1 2025, and down 24.58% quarter-over-quarter from $480000.0 in Q4 2025.
Pliant Therapeutics (PLRX) Accounts Payables (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Accounts Payables for 8 consecutive years, with $362000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 93.56% year-over-year to $362000.0; the TTM figure through Mar 2026 stood at $362000.0 (down 93.56% YoY), while the FY2025 annual figure was $480000.0, down 91.95% from the prior year.
- Accounts Payables declined to $362000.0 in Q1 2026 per PLRX's latest filing, from $480000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $7.3 million in Q1 2024 and bottomed at $362000.0 in Q1 2026.
- Historically, Accounts Payables has averaged $3.3 million across 5 years, with a median of $3.2 million in 2022.
- Annual changes were most pronounced in 2024 — Accounts Payables jumped 416.35% — and 2026, when it tumbled 93.56%.
- Pliant Therapeutics' Accounts Payables stood at $1.6 million in 2022, then soared by 186.77% to $4.5 million in 2023, then surged by 31.54% to $6.0 million in 2024, then slumped by 91.95% to $480000.0 in 2025, then dropped by 24.58% to $362000.0 in 2026.
- Business Quant data shows PLRX's Accounts Payables at $362000.0 in Q1 2026, $480000.0 in Q4 2025, and $485000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | 1.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.53 Mn |
| Mar 31, 2026 | 362,000.00 |
| Dec 31, 2025 | 480,000.00 |
| Sep 30, 2025 | 485,000.00 |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 5.62 Mn |
| Dec 31, 2024 | 5.96 Mn |
| Sep 30, 2024 | 6.89 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Mar 31, 2024 | 7.33 Mn |
| Dec 31, 2023 | 4.53 Mn |
| Sep 30, 2023 | 3.36 Mn |
| Jun 30, 2023 | 2.31 Mn |
| Mar 31, 2023 | 1.42 Mn |
| Dec 31, 2022 | 1.58 Mn |
| Sep 30, 2022 | 3.21 Mn |
| Jun 30, 2022 | 3.12 Mn |
| Mar 31, 2022 | 4.68 Mn |
| Dec 31, 2021 | 2.97 Mn |
| Sep 30, 2021 | 2.61 Mn |